Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    CHF5074
Show Display Options
Rank Status Study
1 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x;   Drug: Placebo
2 Completed Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects
Condition: Alzheimer's Disease
Interventions: Drug: CHF5074 1x;   Drug: CHF5074 2x;   Drug: CHF5074 3x;   Drug: Placebo
3 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x
4 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x
5 Completed Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074;   Drug: CHF 5974
6 Completed Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074;   Drug: placebo
7 Withdrawn Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: Placebo

Indicates status has not been verified in more than two years